Diving Medical Advisory Council

ProSciento Receives 2023 Innovation Award from The Liver Coalition of San Diego

Retrieved on:

Tuesday, October 17, 2023

Chicago Innovation Awards, Doctor of Philosophy, MD, Organization, Liver disease, NASH, St. Luke's Texas Liver Coalition, Therapy, Fatty liver disease, SAN, Hepatology, Diving Medical Advisory Council, Coalition, Patient, Pharmaceutical industry

SAN DIEGO, Oct. 17, 2023 /PRNewswire/ -- ProSciento, Inc. is pleased to announce that they are a recipient of the 2023 Innovation Award from The Liver Coalition of San Diego, champions for liver health and patient support in the region.

Key Points:

SAN DIEGO, Oct. 17, 2023 /PRNewswire/ -- ProSciento, Inc. is pleased to announce that they are a recipient of the 2023 Innovation Award from The Liver Coalition of San Diego, champions for liver health and patient support in the region.
The Coalition's Annual Liver Excellence Gala, which has celebrated liver disease pioneers since 2011, takes place at the Don Room El Cortez San Diego on Sunday, October 29, 2023.
Since its inception in 2017 by the Coalition's Medical Advisory Council, the Innovation Award has recognized leading companies and organizations advancing liver disease treatments.
"The selection of ProSciento as this year's recipient underscores our commitment to recognizing scientific innovation in the treatment of liver diseases, especially nonalcoholic steatohepatitis (NASH)," commented Gabriel Schnickel, MD, Chair of the Liver Coalition of San Diego's Medical Advisory Council.

INTERNATIONALLY RENOWNED DERMATOLOGIST AND PHYSICIAN SCIENTIST SHAWN KWATRA, MD, NAMED NEW CHAIR OF DERMATOLOGY AT THE UM SCHOOL OF MEDICINE AND CHIEF OF SERVICE OF DERMATOLOGY AT UM MEDICAL CENTER

Retrieved on:

Monday, September 18, 2023

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.

Key Points:

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.
Dr. Kwatra joins UMSOM from Johns Hopkins University School of Medicine, where he served as the Founding Director of the Johns Hopkins Itch Center.
"It is an honor to be the next Chair of Dermatology at such a prestigious medical school," said Kwatra.
He earned his undergraduate degree from Duke University and his medical degree from Wake Forest University School of Medicine.

Phoenix Children's Expands Pediatric Orthopedic Surgery Team with Hire of Globally Renowned Brittle Bone Expert

Retrieved on:

Monday, September 11, 2023

Maegen Wallace, MD, MBA , a pediatric orthopedic surgeon and expert in osteogenesis imperfecta, or brittle bone disease, joined the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's last month.

Key Points:

Maegen Wallace, MD, MBA , a pediatric orthopedic surgeon and expert in osteogenesis imperfecta, or brittle bone disease, joined the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's last month.
At the Herbert J. Louis Center for Orthopedics and Sports Medicine at Phoenix Children's, Dr. Wallace will focus on lower-extremity issues, osteogenesis imperfecta and other rare skeletal diseases .
On the research front, she will continue her work to define best clinical practices for patients with brittle bone disease and uncover new treatment options.
"Phoenix Children's emphasis on research and the chance to work once again with Dr. Halanski are what drew me to Phoenix Children's," said Dr. Wallace.

Hydrinity Accelerated Skin Science Names Internationally Recognized Dermatologist Dr. Suneel Chilukuri as Chief Medical Advisor

Retrieved on:

Tuesday, May 2, 2023

Abstract, Partnership, Skin, Hyaluronic acid, Regenerative medicine, Diving Medical Advisory Council, Patient, Pharmaceutical industry

NEW YORK, May 2, 2023 /PRNewswire/ -- Hydrinity Accelerated Skin Science today announced the appointment of Dr. Suneel Chilukuri, M.D., F.A.A.D, F.A.C.M.S as the brand's new Chief Medical Advisor.

Key Points:

NEW YORK, May 2, 2023 /PRNewswire/ -- Hydrinity Accelerated Skin Science today announced the appointment of Dr. Suneel Chilukuri, M.D., F.A.A.D, F.A.C.M.S as the brand's new Chief Medical Advisor.
In this role, Dr. Chilukuri will chair the Hydrinity Accelerated Skin Science industry leading multi-disciplinary Medical Advisory Board.
Dr. Chilukuri is a board-certified dermatologist and an internationally recognized expert on cosmetic and reconstructive surgery.
"We are thrilled to welcome Dr. Chilukuri to the Hydrinity team as our Chief Medical Advisor," says Keith O'Briant, CEO of Hydrinity Accelerated Skin Science.

Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

Retrieved on:

Wednesday, January 18, 2023

FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced the formation of a medical advisory board (the “Medical Advisory Board”) comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric medicine, and foot and ankle surgery.

Key Points:

FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced the formation of a medical advisory board (the “Medical Advisory Board”) comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric medicine, and foot and ankle surgery.
The Company believes that the Medical Advisory Board will support the strategic alignment of patient, payor, and provider goals to help advance the ongoing commercialization of its AC5® Advanced Wound System (“AC5”).
“We are honored to draw on the expertise of these industry leaders as we continue to pursue our mission of creating a better patient experience for those with challenging chronic and acute surgical wounds, while simultaneously improving value for both payors and medical practices,” stated Terrence W. Norchi, MD, President and Chief Executive Officer of Arch.
“We believe the combined experience and expertise of this Medical Advisory Board will help drive the continued adoption and utilization of AC5, as well as potentially shape our work for years to come.”
Arch welcomes the following six members to its Medical Advisory Board:
Dr. Gregory A. Bohn, MD, FACS, ABPM/UHM, MAPWCA, CWSP, board-certified in General Surgery and Hyperbaric Medicine, and President of the American Board of Wound Healing;
Dr. Matthew G. Garoufalis, DPM, FASPS, FACPM, CWS, board-certified in Podiatric Medicine and Foot and Ankle Surgery, Chief Medical Officer of Advanced Oxygen Therapy Inc., and key opinion leader on diabetic foot care, lower extremity wound care, and limb salvage;
Dr. John C. Lantis, MD, FACS, Chief and Professor of Surgery at Mount Sinai West Hospital and the Icahn School of Medicine, and key opinion leader on limb salvage and lower extremity wound healing;
Dr. Brock A. Liden, DPM, FABWH, FAPWCA, board-certified in Podiatry, attending physician at WAFL, and expert lecturer on wound care, podiatric medicine, surgery, and practice management; and,
Dr. Terry A. Treadwell, MD, FACS is a vascular surgeon, Medical Director of the Institute of Advanced Wound Care in Montgomery, Alabama, and renowned lecturer on chronic wound care.

Direct Relief's Fund for Health Equity Awards $22.7 Million to 71 Healthcare Organizations

Retrieved on:

Monday, December 12, 2022

SANTA BARBARA, Calif., Dec. 12, 2022 /PRNewswire/ -- Direct Relief today announced the latest round of grants awarded from its Fund for Health Equity.

Key Points:

SANTA BARBARA, Calif., Dec. 12, 2022 /PRNewswire/ -- Direct Relief today announced the latest round of grants awarded from its Fund for Health Equity.
Direct Relief is incredibly grateful for the work they do every day," said Dr.Byron Scott, MD, MBA, Co-Chair of the Fund for Health Equity and Board Director of Direct Relief and Chair of its Medical Advisory Council.
This year, the Fund is awarding 10 organizations with more than $1.6 million.
We look forward to our continued partnership with Direct Relief's Fund for Health Equity to further support community-based organizations focused on advancing health equity."

bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board

Retrieved on:

Thursday, November 10, 2022

Research, Surgery, Medical Devices, Genetics, Biotechnology, Radiology, Health, Science, Oncology, Diving Medical Advisory Council, Lung cancer staging, Asthma, LDT, Research, Waterbury, Connecticut, University, Population, Diagnosis, Disease, Flow cytometry, American Lung Association, Medical University of South Carolina, Company, Medical school, Forward-looking statement, Science, Laboratory developed test, Lung, Assistant, Time, Patient, Environmental medicine, National Farm Medicine Center, FCCP, CT, Doctor of Philosophy, BIAF, Cancer, DNA repair, Physician, Yale University, Laboratory, University of Texas Southwestern Medical Center, Indiana University School of Medicine, Yale School of Medicine, Veteran, Lung cancer, Technology, Behavior, Mortality, DNA, DRS, NASDAQ, Sputum, MS, National Board of Medical Examiners, Prognosis, LLC, Pharmaceutical industry, Medical device, Medical imaging, MD, Medicine

The caliber of the physicians and researchers who accepted our invitation to join our Scientific and Medical Advisory Board will accelerate the work of our own scientists to bring breakthrough technology to the early diagnosis of cancer.

Key Points:

The caliber of the physicians and researchers who accepted our invitation to join our Scientific and Medical Advisory Board will accelerate the work of our own scientists to bring breakthrough technology to the early diagnosis of cancer.
Habib and Hill join Science and Medical Advisory Board members Neil Alexis, PhD, Catherine Sears, MD, and Gerard Silvestri, MD.
Gerard Silvestri , MD, MS, FCCP, Professor of Medicine and Lung Cancer Pulmonologist at the Medical University of South Carolina.
Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

Four Seasons Expands Collaboration with Johns Hopkins Medicine International Through Award-winning Lead With Care Program

Retrieved on:

Thursday, November 10, 2022

TORONTO, Nov. 10, 2022 /PRNewswire/ -- Four Seasons and Johns Hopkins Medicine International have announced that they are expanding the collaboration that began in 2020, building upon the learnings and success of Four Seasons Lead With Care program. The renowned health care expertise of Johns Hopkins Medicine, combined with the celebrated service excellence of Four Seasons, will continue to advance the leading luxury hospitality company's longstanding commitment to protecting the health, safety and security of its employees, guests and residents worldwide.

Key Points:

The renowned health care expertise of Johns Hopkins Medicine, combined with the celebrated service excellence of Four Seasons, will continue to advance the leading luxury hospitality company's longstanding commitment to protecting the health, safety and security of its employees, guests and residents worldwide.
"Throughout the pandemic, Johns Hopkins Medicine experts have been trusted health and safety advisors for our company and our property teams around the world," says Alejandro Reynal , President and Chief Executive Officer, Four Seasons Hotels and Resorts.
Johns Hopkins Medicine International's decades-long leadership in collaborating with organizations worldwide to enhance health care safety and quality has been key to the development and success of Lead With Care.
Johns Hopkins Medicine International looks forward to embarking on a new phase of this unique collaboration between world leaders in hospitality and world leaders in biomedical research, medical education and clinical care, according to Charles Wiener, M.D., President of Johns Hopkins Medicine International and Professor of Medicine and Physiology at the Johns Hopkins University School of Medicine.

Accumen appoints highly regarded physician to Medical Advisory Council

Retrieved on:

Thursday, October 13, 2022

Scottsdale, AZ, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Andrew Fletcher, MD, MBA, CPE, CHCQM, FCAP has been appointed to the Medical Advisory Council at Accumen, specializing in Lab Stewardship.

Key Points:

Scottsdale, AZ, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Andrew Fletcher, MD, MBA, CPE, CHCQM, FCAP has been appointed to the Medical Advisory Council at Accumen, specializing in Lab Stewardship.
Dr. Fletcher is a board-certified anatomic/clinical pathologist, certified physician executive and a fellow of the American Board of Quality Assurance and Utilization Review Physicians.
Dr. Fletcher is a strong addition to our Medical Advisory Council.
Accumen helps hospitals and health systems respond to current challenges and even thrive in todays unpredictable and ever-changing environment.

Extracorporeal Blood Filter Removes Circulating Tumor Cells

Retrieved on:

Tuesday, September 20, 2022

Research, Other Health, General Health, Oncology, Medical Devices, Infectious Diseases, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Seraph, Diving Medical Advisory Council, OS, Breast, Radiation, ASAP, Virus, Blood, Person, Infection, Patient, Technology, Deutsche Gesellschaft für Ur- und Frühgeschichte, Metastasis, Fungus, Research, Animal, Communication, DARPA, Death, Adsorption, EUA, Probability, COVID-19, NFCR, Jean-Louis Vincent, Sepsis, IDE, Life, Pandemic, Leukemia, CE, Nominal interest rate, Q2, Bloodstream infections, Trial of the century, FDA, MD, Population, Chinese, News, CEO, Bacteria, Heparin, Hospital, Cancer, Conjugated estrogens, National Foundation for Cancer Research, Prostate, Immunotherapy, Investigational device exemption, Immunodeficiency, Lung, CTC, Medical imaging, Pharmaceutical industry, Vaccine, EU

However, no therapy is currently available to remove CTCs directly from the blood in quantities that could extend OS.

Key Points:

However, no therapy is currently available to remove CTCs directly from the blood in quantities that could extend OS.
Higher counts of CTC and CE cells in the blood are linked to higher probability of death.
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph 100 Microbind Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients.
As a patient's blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body.